RecruitingNCT06691321

Caspofungin for Pneumocystis Pneumonia in PLWHIV.

Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV/AIDS.

Sponsor

Instituto Nacional de Enfermedades Respiratorias

Enrollment

60 participants

Start Date

Aug 1, 2023

Study Type

OBSERVATIONAL

Conditions

HIV-1-infection Pneumocystis Pneumonia

Summary

Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is testing caspofungin — an antifungal medication — as an additional treatment for Pneumocystis pneumonia (PCP), a serious lung infection caused by a fungus called Pneumocystis jirovecii, in people living with HIV. Standard treatment for PCP uses a combination of antibiotics, and this study is exploring whether adding caspofungin improves outcomes. **You may be eligible if...** - You are living with HIV - You have been diagnosed with probable or confirmed Pneumocystis pneumonia (PCP) - You have relevant lab and diagnostic tests performed at the time of hospital admission **You may NOT be eligible if...** - You have not been diagnosed with PCP - You have severe allergies to the study drug - You have certain serious organ conditions that would make treatment unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.